Prolor Biotech (PBTH +4.2%) gets a boost from an orphan drug designation for hGH-CTP, a...

|By:, SA News Editor

Prolor Biotech (PBTH +4.2%) gets a boost from an orphan drug designation for hGH-CTP, a long-acting treatment for growth hormone deficiency from the European Commission and the European Medicines Agency. The approval marks the first time a growth hormone has received any such a designation in Europe, and once launced, the drug will receive 10 years of marketing exclusivity in Europe.